Probing the physicochemical and structural requirements for glycogen synthase kinase-3α inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides
- 1 December 2006
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 14 (24) , 8210-8218
- https://doi.org/10.1016/j.bmc.2006.09.021
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Glycogen synthase kinase 3: a drug target for CNS therapiesJournal of Neurochemistry, 2004
- Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 DiabetesCurrent Pharmaceutical Design, 2004
- GSK-3α regulates production of Alzheimer's disease amyloid-β peptidesNature, 2003
- Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal MuscleDiabetes, 2002
- Regulation of tau phosphorylation and protection against β‐amyloid‐induced neurodegeneration by lithium. Possible implications for Alzheimer's diseaseBipolar Disorders, 2002
- Role of glycogen synthase kinase-3 in skeletal muscle insulin resistance in Type 2 diabetesJournal of Diabetes and its Complications, 2002
- Glycogen Synthase Kinase-3: Properties, Functions, and RegulationChemical Reviews, 2001
- Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.Diabetes, 1999
- The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1The FASEB Journal, 1995
- Glycogen Synthase Kinase‐3 from Rabbit Skeletal MuscleEuropean Journal of Biochemistry, 1980